536 related articles for article (PubMed ID: 15786866)
1. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
Lottersberger J; Salvetti JL; Beltramini LM; Tonarelli G
Rev Argent Microbiol; 2004; 36(4):151-7. PubMed ID: 15786866
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
[TBL] [Abstract][Full Text] [Related]
4. Gag-derived proteins of HIV-1 isolates from Indian patients: cloning, expression, and purification of p17 of B- and C-subtypes.
Gupta S; Arora K; Gupta A; Chaudhary VK
Protein Expr Purif; 2001 Apr; 21(3):378-85. PubMed ID: 11281711
[TBL] [Abstract][Full Text] [Related]
5. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
[TBL] [Abstract][Full Text] [Related]
6. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children.
Goulder PJ; Brander C; Annamalai K; Mngqundaniso N; Govender U; Tang Y; He S; Hartman KE; O'Callaghan CA; Ogg GS; Altfeld MA; Rosenberg ES; Cao H; Kalams SA; Hammond M; Bunce M; Pelton SI; Burchett SA; McIntosh K; Coovadia HM; Walker BD
J Virol; 2000 Jun; 74(12):5679-90. PubMed ID: 10823876
[TBL] [Abstract][Full Text] [Related]
7. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
Thakar MR; Bhonge LS; Lakhashe SK; Shankarkumar U; Sane SS; Kulkarni SS; Mahajan BA; Paranjape RS
J Infect Dis; 2005 Sep; 192(5):749-59. PubMed ID: 16088824
[TBL] [Abstract][Full Text] [Related]
8. Decline in CTL and antibody responses to HIV-1 p17 and p24 antigens in HIV-1-infected hemophiliacs irrespective of disease progression. A 5-year follow-up study.
O'Toole CM; Lowdell MW; Chargelegue D; Colvin BT
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1361-8. PubMed ID: 1281655
[TBL] [Abstract][Full Text] [Related]
9. Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients.
Broliden PA; Morfeldt-Månsson L; Rosen J; Jondal M; Wahren B
Clin Exp Immunol; 1989 May; 76(2):216-21. PubMed ID: 2503275
[TBL] [Abstract][Full Text] [Related]
10. Immune responses to six synthetic peptides of capsid protein with sera from HIV-1 infected individuals.
Liu G; Yang L; Wang J; Zhang G; Chen X; Zheng Y
Cell Mol Immunol; 2005 Aug; 2(4):289-93. PubMed ID: 16274627
[TBL] [Abstract][Full Text] [Related]
11. Immunodominant epitopes of HIV-1 p17 and p24.
Graham S; Follett EA; Wallace L; Desselberger U; Marsden HS
AIDS Res Hum Retroviruses; 1992 Oct; 8(10):1781-8. PubMed ID: 1280955
[TBL] [Abstract][Full Text] [Related]
12. Human monoclonal antibodies to HIV-1: cross-reactions with gag and env products.
Pollock BJ; McKenzie AS; Kemp BE; McPhee DA; D'Apice AJ
Clin Exp Immunol; 1989 Dec; 78(3):323-8. PubMed ID: 2482145
[TBL] [Abstract][Full Text] [Related]
13. The use of synthetic peptides in the diagnosis of HIV infections.
Petrov RV; Khaitov RM; Sidorovich IG; Pavlikov SP; Nikolaeva IA; Ivachenko ME; Andreev SM; Sklyarov LYu
Biomed Sci; 1990 Mar; 1(3):239-44. PubMed ID: 2103826
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of synthetic peptides for the detection of antibodies against human immunodeficiency virus].
Lottersberger J; Salvetti JL; Tonarelli G
Rev Argent Microbiol; 2003; 35(3):149-55. PubMed ID: 14587377
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics analysis of HIV-1 matrix protein: clarifying differences between crystallographic and solution structures.
Verli H; Calazans A; Brindeiro R; Tanuri A; Guimarães JA
J Mol Graph Model; 2007 Jul; 26(1):62-8. PubMed ID: 17067836
[TBL] [Abstract][Full Text] [Related]
16. Use of the presence of anti-protein gag antibodies as an evolution marker of HIV infection.
Neguţ EA; Usein CR; Sfartz S; Zugun-Eloae F
Roum Arch Microbiol Immunol; 1999; 58(2):131-46. PubMed ID: 11845452
[TBL] [Abstract][Full Text] [Related]
17. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.
Pincus SH; Messer KG; Nara PL; Blattner WA; Colclough G; Reitz M
J Clin Invest; 1994 Jun; 93(6):2505-13. PubMed ID: 7515393
[TBL] [Abstract][Full Text] [Related]
18. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
Ota A; Tanaka-Taya K; Ueda S
Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
[TBL] [Abstract][Full Text] [Related]
19. Reactivities of HIV-1 gag-derived peptides with antibodies of HIV-1-infected and uninfected humans.
Haist S; März J; Wolf H; Modrow S
AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1909-17. PubMed ID: 1489579
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and persistence of antibody titers to recombinant HIV-1 core and matrix proteins in HIV-1 infection.
Janvier B; Mallet F; Cheynet V; Dalbon P; Vernet G; Besnier JM; Choutet P; Goudeau A; Mandrand B; Barin F
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):898-903. PubMed ID: 8315575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
